Wire · regulatory
Replimune melanoma drug wins support of FDA panel
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 1 August 2026 · Fusion42 review
An FDA advisory committee has voted in favour of Replimune's melanoma drug, despite ongoing concerns from FDA scientists, potentially paving the way for the company after two previous rejections.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You have a clearer path to the US market if you develop melanoma treatments as Replimune's vote shows FDA advisers may accept renewed applications after prior rejections. Timing your regulatory submissions now could avoid stalled launches.
◆ Coverage
1 source · 31 Jul 2026
◆ Related on Wire
◆ Topics
Biotechfdadrug-approvalmelanomareplimune